JNJ -6.02% NVDA +0.13% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Johnson & Johnson (NYSE:JNJ) stock tumbled 6.8% through 12:30 p.m. ET Tuesday despite delivering an earnings beat this morning and raising guidance for the rest of 2026.
Heading into earnings day, analysts expected Johnson & Johnson to earn $2.53 in "adjusted" earnings on $25.4 billion in sales for Q3. In fact, J&J says it earned $2.59 per share, adjusted, and beat slightly on sales as well.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Johnson & Johnson grew its sales 5.9% in Q3, but despite beating on earnings, its adjusted profit was down 7.5% -- and its GAAP profit was down much, much more. Blaming a "one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines" for the news, J&J admitted that its Q3 earnings calculated under generally accepted accounting principles (GAAP) came to just $0.09 per share.
So you can see why investors were just a wee bit upset with the news. But should they be?
Yes, earnings were down dramatically, but on the plus side, free cash flow increased more than 6% to $15.1 billion. What's more, the declines were expected, and ended up being less bad than feared. On top of all that, J&J raised its guidance for the rest of this year. Management now anticipates that 2026 sales will grow 7.4% to $101.2 billion, and its adjusted earnings could be $11.10 per share.
My problem with all this, though, is that... it's not enough.
Valued even on adjusted earnings, Johnson & Johnson stock costs more than 22x earnings. Valued on free cash flow, the multiple is closer to 29x. I just don't see how 7%-ish growth is good enough to support that.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $380,795!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,390,634!*
Now, it's worth noting Stock Advisor's total average return is 946% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of October 13, 2026.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
Why Johnson & Johnson Stock Dropped Today was originally published by The Motley Fool
